Cooper Companies (NYSE: COO – Get Rating) had its price objective reduced by Piper Sandler from $ 425.00 to $ 375.00 in a research report issued on Friday, The Fly reports. The firm currently has an “overweight” rating on the company’s medical device stock. Piper Sandler’s target price would suggest a potential upside of 20.36% from the company’s previous close.
COO has been the topic of a number of other research reports. Robert W. Baird lowered their price objective on Cooper Companies from $ 437.00 to $ 392.00 in a research note on Thursday, May 26th. Wells Fargo & Company lowered their price objective on Cooper Companies from $ 495.00 to $ 380.00 and set an “overweight” rating on the stock in a research note on Monday, May 23rd. Stephens lowered their price objective on Cooper Companies from $ 500.00 to $ 460.00 and set an “overweight” rating on the stock in a research note on Friday, June 3rd. KeyCorp lowered their price objective on Cooper Companies from $ 414.00 to $ 408.00 and set an “overweight” rating on the stock in a research note on Friday, June 3rd. Finally, StockNews.com began coverage on Cooper Companies in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus target price of $ 426.78.
NYSE: COO opened at $ 311.57 on Friday. The stock has a market cap of $ 15.37 billion, a P / E ratio of 16.36, a PEG ratio of 2.18 and a beta of 0.92. The stock has a 50 day simple moving average of $ 329.13 and a 200 day simple moving average of $ 377.68. The company has a current ratio of 1.05, a quick ratio of 0.69 and a debt-to-equity ratio of 0.33. Cooper Companies has a 1-year low of $ 297.34 and a 1-year high of $ 463.59.
Cooper Companies (NYSE: COO – Get Rating) last released its quarterly earnings results on Thursday, June 2nd. The medical device company reported $ 3.24 earnings per share for the quarter, missing the consensus estimate of $ 3.43 by ($ 0.19). Cooper Companies had a return on equity of 9.48% and a net margin of 30.20%. The firm had revenue of $ 829.80 million for the quarter, compared to analyst estimates of $ 821.03 million. During the same period in the previous year, the business posted $ 3.38 earnings per share. The business’s revenue for the quarter was up 15.3% on a year-over-year basis. As a group, sell-side analysts forecast that Cooper Companies will post 13.2 EPS for the current year.
In related news, Director Gary S. Petersmeyer sold 300 shares of the business’s stock in a transaction on Monday, April 11th. The stock was sold at an average price of $ 410.55, for a total transaction of $ 123,165.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 1.70% of the company’s stock.
A number of hedge funds have recently modified their holdings of COO. Veritas Asset Management LLP grew its position in Cooper Companies by 12.0% during the 4th quarter. Veritas Asset Management LLP now owns 2,001,678 shares of the company’s medical device stock worth $ 838,583,000 after acquiring an additional 214,700 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Cooper Companies by 24.2% during the 1st quarter. Bank of New York Mellon Corp now owns 1,089,699 shares of the company’s medical device stock worth $ 455,046,000 after buying an additional 212,257 shares during the period. JPMorgan Chase & Co. lifted its holdings in Cooper Companies by 17.4% during the 1st quarter. JPMorgan Chase & Co. now owns 1,120,044 shares of the company’s medical device stock worth $ 467,719,000 after buying an additional 165,647 shares during the period. BlackRock Inc. lifted its holdings in Cooper Companies by 4.1% during the 4th quarter. BlackRock Inc. now owns 4,000,869 shares of the company’s medical device stock worth $ 1,676,126,000 after buying an additional 158,358 shares during the period. Finally, Invesco Ltd. lifted its holdings in Cooper Companies by 10.8% during the 1st quarter. Invesco Ltd. now owns 1,620,188 shares of the company’s medical device stock worth $ 676,575,000 after buying an additional 157,305 shares during the period. Institutional investors and hedge funds own 98.38% of the company’s stock.
Cooper Companies Company Profile (Get Rating)
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigue in the Americas, Europe, Middle East, Africa, and Asia Pacific.
Receive News & Ratings for Cooper Companies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cooper Companies and related companies with MarketBeat.com’s FREE daily email newsletter.